Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2010 May;55(5):469–480. doi: 10.1097/FJC.0b013e3181d64dbe

Figure 6. PDGF-stimulated CK2 catalytic subunit expression and activity are inhibited by TRO in PA SMCs.

Figure 6

PA SMCs were grown in DMEM containing 10% fetal calf serum, and transferred to medium containing 0.2% serum 24 hours prior to the of 25 ng/ml PDGF with and without 1 uM TRO. A) At the times indicated above each lane, equal amounts of lysate protein were resolved on polyacrylamide-SDS gels and transferred to PVDF membranes. The membranes were probed with antibody against CK2 catalytic subunit. The representative blot shows that PDGF stimulates CK2 catalytic subunit expression in time-dependent manner, but that this process is blocked by TRO B) Forty-eight hours post PDGF/TRO addition, cells were lysed and approximately 20 ug of lysate protein were assayed for CK2 activity as described in Experimental Procedures. Triplicate reactions were run in the presence or absence of CK2 inhibitor. The non-specific activity measured in the reactions containing inhibitor was subtracted from activity measured in reactions without inhibitor. The graph shows average kinase activity relative to reactions performed with lysate protein from cells not exposed to PDGF or TRO. * indicates p≤0.05.